Biotheranostics hologic login
WebJan 5, 2024 · Hologic, Inc. (Nasdaq: HOLX), a global leader in women's health, announced today that it has agreed to acquire Biotheranostics, Inc., a privately held, commercial-stage company that provides molecular diagnostic tests for breast and metastatic cancers, for approximately $230 million, subject to working capital and other customary closing … WebHologic announced a $230 million deal in which it will acquire Biotheranostics, a private company that provides molecular diagnostic tests for breast and metastatic cancers. Through the purchase, Hologic aims to enhance its current work in the field of oncology with more personalized treatment and better outcomes for women.
Biotheranostics hologic login
Did you know?
WebJan 6, 2024 · January 6, 2024 By Sean Whooley. Hologic (NSDQ: HOLX) announced that it agreed to acquire molecular diagnostic test maker Biotheranostics for approximately $230 million. Privately held, commercial ... WebJan 5, 2024 · MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic, Inc. (Nasdaq: HOLX), a global leader in women's health, announced today that it has agreed to acquire Biotheranostics, Inc., a privately held, commercial-stage company that provides molecular diagnostic tests for breast and metastatic cancers, for approximately $230 million, …
WebJan 6, 2024 · M edical technology company Hologic Inc. has announced the acquisition of privately-held Biotheranostics Inc. in a deal worth $230 million. Shares of Hologic, which closed 4% higher on Tuesday ... WebFeb 22, 2024 · MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic, Inc. (Nasdaq: HOLX), a global leader in women's health, has completed its previously announced …
WebAccess and use of the Biotheranostics Web site is subject to the terms and conditions set forth herein and all applicable laws, statutes, and/or regulations. Biotheranostics does not, by or through this Web site, offer for sale any products or services. Biotheranostics may revise or modify these terms and conditions from time to time. WebSign in or register to place Hologic product orders online (consumables only), download and view secure product documentation, search employment opportunities and set up job alerts or access training …
WebBiotheranostics, Inc. has been acquired by Hologic. Hologic is an innovative medical technology company whose purpose is to enable healthier lives everywhere, every day. While we discover and ...
WebJan 5, 2024 · MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic, Inc. (Nasdaq: HOLX), a global leader in women's health, announced today that it has agreed to acquire … sic632 datasheethttp://www.biotheranostics.com/privacy-policy.html sic635cd-t1-ge3-aWebShip with specimen to Biotheranostics' laboratory OR fax this form to 800-266-9607 and Biotheranostics will request the specimen from Pathology. NeoTYPE Discovery Profile ... Biotheranostics, Inc., A Hologic Company 9640 Towne Centre Drive Suite 200 San Diego, CA 92121 www.CancerTYPEID.com Client Services (877) 886-6739 Fax (800) … the perfume shop phone numberWebHologic said the acquisition of Biotheranostics will give it a company that operates in markets that are adjacent and complementary to its own. ... Also in the long run, Hologic may configure Biotheranostics' tests to run on Hologic's Panther Fusion platform, Thornal added. Kumar noted that if that can be accomplished, it could enable a ... the perfume shoppe scottsdaleWebCancerTYPE ID ® is performed and billed separately by NeoGenomics’ contracted reference laboratory, Biotheranostics, Inc., an independent CLIA-licensed and CAP … the perfume shop peterboroughWebJan 5, 2024 · On January 5, 2024, Hologic acquired life science company Biotheranostics for 230M USD Acquisition Highlights. This is Hologic’s 2nd transaction in the Life Science sector. This is Hologic’s 7th largest (disclosed) transaction. This is Hologic’s 15th transaction in the United States. This is Hologic’s 4th transaction in California. sic635WebIn a clinical study of 547 patients considered to be clinically low risk (T1N0), Breast Cancer Index identified ~25% as likely to benefit from extended endocrine therapy and high risk of late distant recurrence. References: 1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ®) for Breast ... the perfume shop pinellas park